|
Vigabatrin
drug data and news
Vigabatrin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Vigabatrin
|
| Brand Names/Synonyms |
CHEMBANK1798; GVG; Gamma-Vinyl Gaba; Sabril; Vigabatrin; Vigabatrin [Usan:Ban:Inn]; Vigabatrina [Spanish]; Vigabatrine; Vigabatrine [French]; Vigabatrinum [Latin]; [Latin]; [Usan:Ban:Inn] |
| Indication |
Used for the treatment of refractory seizure disorders (epilepsy, complex partial seizures, seconday generalized seizures and infantile spasms in West syndrome |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Vigabatrin, although chemically unrelated to other anticonvulsants, is an anticonvulsant used to treat tonic-clonic seizures, complex partial seizures, absence seizures, myoclonic seizures, bipolar disorder, and migraines. It inhibits the catabolism of GABA. |
| Mechanism Of Action |
Vigabatrin is an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the catabolism of GABA. Gamma-aminobutyric acid (GABA), is an inhibitory neurotransmitter in the CNS. This inhibition increases the level of GABA in the synapses. Vigabatrin is a racemic compound, and its [S]-enantiomer is pharmacologically active. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Vigabatrin is an analog of GABA but is not a receptor agonist. |
Vigabatrin News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
POWDER; TABLETS |
| Drug_Category |
Anticonvulsants; Enzyme Inhibitors; ATC:N03AG04 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Can cause visual field constriction. Other side effects include fatigue, weight gain, headaches, dizziness, somnolence and hyperactivity |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
4-aminohex-5-enoic acid |
| Chemical Formula |
C6H11NO2 |
| Molecular Weight |
129.157 g/mol |
| Smiles String |
C=CC(CCC(=O)O)N |
| Melting Point |
Not Available |
| Water Solubility |
55.1 mg/mL |
| State |
Solid |
| LogP/Hphobicity |
0.056 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Almost no metabolic transformation occurs |
| Half Life |
5-8 hours |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.drugs.com/cons/Vigabatrin.html |
| Drug Type |
Approved Drug |
| Accession No |
APRD00282 |
| CAS Registry Number |
60643-86-9 |
| KEGG Compound ID |
C07500 |
| PubChem ID |
SID:9703 |
| PharmGKB ID |
PA10231 |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
2068036
|
|
|
